Cleveland·Miami·Basel·Tel AvivForce Multipliers  ·  Elevate Humanity
Home / Insights / Artificial Intelligence
Insights

Artificial Intelligence

Artificial intelligence is the accelerant across the LeverVenture mandate in life sciences and healthcare, never a sector of its own. These pieces cover how AI and the technologies around it are put to work, and what implementation asks of the operators responsible for it.

Field notes, diligence method, operating and capital Written by the partner or operator who did the work
§ 01  /  02
The archive

Filed under Artificial Intelligence, newest first.

The most recent piece leads and every other piece in this category follows it, each with the line that says what it covers. The other categories are one link away.

Most recent
Artificial Intelligence27 Aug 2026  ·  11 min read

AI Diligence: Eleven Questions, and What the Regulatory Record Answers

Eleven AI due diligence questions for healthcare companies, each answered from a named FDA De Novo or 510(k) record: indication, autonomy, evidence, inputs, change control and holder.

Peleg ChevionBy Peleg Chevion
Read the piece
Browse by category
By author

Artificial Intelligence

The full index

Everything else filed under Artificial Intelligence, newest first.

Artificial Intelligence17 Jul 2026  ·  7 min

Digital Transformation as an Investment Thesis: Why Most Programs Fail and How Operator-Led Capital Fixes Them

Most digital transformation programs fail because they are scoped as projects, not as changes to unit economics. An operator-led growth equity view of what actually compounds — and how founders can tell the real from the theater.

Read this piece
Artificial Intelligence27 Jan 2026  ·  11 min

Which AI Healthcare Claims Survive a Regulatory Record

FDA device classification works as a filter for AI claims. On the FDA's December 2025 AI-enabled device list, 1,304 of 1,357 entries were 510(k) clearances.

Read this piece
Artificial Intelligence11 Aug 2025  ·  8 min

Quantum Computing Investment Thesis: Beyond the Hype to 2028 Reality

Quantum computing has entered its "crossing the chasm" moment. For growth equity investors, the technology is real, but commercial timelines remain uncertain and capital requirements are enormous.

Read this piece
Artificial Intelligence26 May 2025  ·  7 min

Generative AI: Separating Hype from Enterprise Value

Two years after ChatGPT's launch sparked global fascination, the generative AI landscape has matured dramatically. The experimental phase is over.

Read this piece
Artificial Intelligence15 Jan 2025  ·  9 min

AI Implementation Framework for Growth Companies

Most companies have now run an AI pilot. Far fewer have put one into production and kept it there.

Read this piece
§ 02  /  02
Research

The State of Growth Equity, 2026 edition.

The first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.

01

Executive summary

Free, no form. The findings, the method and every chart that carries one — complete, not a teaser, and the same text that opens the full report.

02

The full report

Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no list you did not ask to be on.

Go to the research
Contact

Have a question about something here, or want to discuss it? We would be glad to hear from you.

The 2026 study